Law360, New York (March 17, 2009, 12:00 AM ET) -- A suit filed by a group of direct purchasers of Wellbutrin XL against Biovail Corp. and GlaxoSmithKline PLC alleging that the two engaged in anti-competitive conduct in a patent fight over the antidepressant will move forward, although a district judge dismissed one claim Monday.
Judge Mary A. McLaughlin of the United States District Court for the Eastern District of Pennsylvania dismissed a substantive monopolization claim against Biovail but kept the rest of the claims alive.
GSK and Biovail had both submitted motions to dismiss all claims...
Wellbutrin Antitrust Suit To Proceed On Most Claims
To view the full article, take a free trial now.
